1. PHARMA RESEARCH EMERGING CHALLENGES Arulmoli, Ph.D Vice President-R&D SeQuent Scientific Ltd., Mangalore August 19, 2011
2.
3.
4.
5.
6.
7. Status of New Molecules (NCEs) trials by Indian Cos. New Chemical Entities from Indian Pharma Companies - Status NCEs Company Therapy area Status Target to launch Market Size Global players IN-105 Biocon Diabetes-Insulin Phase -III 2011 in India US $ 13 Bn Nova Nordisk, Eli Lilly 2015 in ROW T 1h Biocon Psoriasis, rhematoid Phased -II Not mentioned US $ 15 Bn Astella, BMS, ABBOTT arthritis Completed Amgen DRF 2593 Dr Reddy Diabetes Phase -III Not mentioned US $ 7 Bn Glaxo, Takeda, Abbott 307 IN PPAR agonists Solvay Crofelemer Glenmark Diarrhoea Phase-III 2011 US $ 2 Bn Glaxo Sun -1334 H Sun Pharma Allergy Phase -II Not mentioned US $ 5 Bn Sanofi-Aventis, Pfizer Completed P 276 Piramal Life Cancer Phase -II To file for market US $ 48 Bn Roche, Eli Lilly, Pfizer approval in 2011 Glaxo GRC 8200 Glenmark Diabetes Phase-II 2013-14 US $ 1-2 Bn Merck DPP IV inhibitor Completed Arterolane Ranbaxy Malaria Phase -III To apply for market US $ 1 Bn Novartis Maleate + approval in 2010 Piperaquine
![[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],PHARMA RESEARCH – EMERGING CHALLENGES Ref: IMS Health Data](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)